(Q36370782)

13 August 2017

1 reference

title

Implications of TNF-α in the pathogenesis and management of GVHD (English)

1 reference

13 August 2017

0 references

0 references

John E Levine

1

0 references

publication date

8 March 2011

1 reference

International Journal of Hematology

13 August 2017

1 reference

13 August 2017

93

1 reference

13 August 2017

5

1 reference

13 August 2017

571-577

1 reference

Elafin is a biomarker of graft-versus-host disease of the skin

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

A biomarker panel for acute graft-versus-host disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

Immunobiology of allogeneic hematopoietic stem cell transplantation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

Toll-like receptor control of the adaptive immune responses

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

The danger model: a renewed sense of self

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

Cytokine dysregulation and acute graft-versus-host disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

Th1 cytokines promote T-cell binding to antigen-presenting cells via enhanced hyaluronan production and accumulation at the immune synapse

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488873

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial

28 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0803-1

Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0803-1

Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor alpha and not by the FasL-Fas interaction: effect of pentoxifylline on the development of mucosal atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0803-1

Two tumour necrosis factor receptors: structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0803-1

Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0803-1

Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0803-1

Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0803-1

Prospective monitoring of tumor necrosis factor alpha and interferon gamma to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0803-1

Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0803-1

Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0803-1

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0803-1

Infliximab for steroid‐refractory acute GVHD: A case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0803-1

Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0803-1

Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease

21 January 2018

1 reference

12 December 2020

Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease

1 reference

12 December 2020

Infliximab treatment for steroid-refractory acute graft-versus-host disease

1 reference

12 December 2020

Infliximab for GVHD therapy in children

1 reference

12 December 2020

Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines

1 reference

12 December 2020

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation

1 reference

12 December 2020

Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice

1 reference

12 December 2020

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors

1 reference

12 December 2020

Graft-versus-host disease

1 reference

12 December 2020

Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation

1 reference

12 December 2020

Graft-versus-host disease

1 reference

12 December 2020

Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

1 reference

12 December 2020

10.1007/S12185-011-0803-1

Identifiers

DOI

1 reference

13 August 2017

1 reference

PMC publication ID

3488873

13 August 2017

PubMed publication ID

21384095

1 reference

PMC publication ID

3488873